Cox-2 and tNSAIDs: Description of users FRESH-PEF2926-en Cécile DROZ-PERROTEAU Cox-2 and tNSAIDs: Description of users CADEUS FRESH-PEF2926-en 2926 FRESH-PEF2926 Patrick BLIN Annie FOURRIER-REGLAT Nicholas MOORE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Epidemiology France Portal (PEF) MSD FRANCE PFIZER (FRANCE) null Patrick;BLIN Annie;FOURRIER-REGLAT Nicholas;MOORE Celebrex NSAIDs traditional non-steroidal anti-inflammatory drugs gastroprotective drugs cardiovascular events gastrointestinal events health authotities (Comité Economique des Produits de Santé) Cyclo-oxygenase 2 coxibs Vioxx use pharmacoepidemiology cohort Department of Pharmacology Bordeaux Rheumatology Healthcare system determinants: Use of care Healthcare system determinants The objective of this study was to better understand the use of anti-inflammatory drugs, cyclo-oxygenase 2 (COX-2) or coxib (Vioxx®, Celebrex®) and traditional anti-inflammatory drugs (tNSAIDs, e.g. Aspirin, Ibuprofen) in France and to describe and assess the risks of adverse events possibly related to treatment. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patient randomly selected from the source population using the following criteria: not dead according to the ERASME database, living in France with a valid address, with dispensation of an NSAIDs of interest during the month preceding selection, with at least one healthcare reimbursement within six months preceding the date of dispensation, for whom the contact details of the prescribing physician were available, not previously selected from the source population, not being listed under guardianship or in prison; patient agreeing to participate in the study Clinical data Participant-reported health data Socio-demographic data Health event/morbidity Health event/mortality Health care consumption and services Other >= 20000 individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study 45 217 patients inclus - 45 217 patients included Unknown To be defined - Approval of the entire study by the Advisory Committee on Research Information Processing in the Health Field and the National Commission for Data Protection and Liberties (CNIL). Ownership of study data was the subject of an agreement between the University Bordeaux Segalen and pharmaceutical companies. Access on specific project only